TABLE 3.

Multivariable logistic regression analysis of epidemiological and clinical factors associated with CPE colonization in the ACH and ILTCFs^a

Factorb	Overall (n = 5,357)			ACH (n = 2,956)			ILTCFs (n = 2,401)
	aOR	95% CI	P	aOR	95% CI	P	aOR	95% CI	P
Age (yr)	0.99	0.97–1.01	0.313	0.99	0.96–1.01	0.347	0.99	0.94–1.04	0.609
Male gender	1.04	0.58–1.88	0.898	1.60	0.76–3.36	0.217	0.27	0.07–1.12	0.072
≤4 beds in the same cubicle	0.95	0.42–2.17	0.907	1.03	0.41–2.56	0.949	0.94	0.12–7.08	0.951
Hospital stay ≥3 wks	1.37	0.69–2.74	0.372	2.67	1.17–6.05	0.019	0.65	0.16–2.73	0.558
Current location
LTCFs	Ref						Ref
ITCFs	4.13	1.08–15.76	0.038				4.32	0.60–31.08	0.146
ACH	4.57	1.14–18.44	0.033
Yr of sample collection
2014	Ref			Ref			Ref
2015	2.61	1.13–6.04	0.025	2.52	0.95–6.64	0.062	2.12	0.34–13.20	0.422
2016	2.98	1.30–6.80	0.010	2.99	1.15–7.75	0.024	2.13	0.32–14.12	0.434
Prior admission to any facilities	0.78	0.38–1.61	0.504	0.70	0.31–1.61	0.405	1.42	0.14–14.20	0.767
Prior ICU admission	1.36	0.33–5.68	0.672	2.84	0.59–13.58	0.192	NA
Prior surgical operations	0.94	0.48–1.86	0.860	0.95	0.42–2.11	0.893	1.14	0.22–5.86	0.873
Prior wound	0.96	0.52–1.79	0.909	0.57	0.26–1.25	0.158	5.30	1.01–27.72	0.048
Prior vascular access procedures	1.29	0.39–4.25	0.681	2.11	0.26–16.95	0.483	0.39	0.06–2.77	0.350
Prior respiratory procedures	1.73	0.75–3.97	0.198	0.86	0.27–2.76	0.795	4.97	1.09–22.71	0.038
Prior gastrointestinal procedures	0.94	0.45–1.95	0.864	0.64	0.25–1.64	0.355	2.59	0.51–13.05	0.249
Prior urinary procedures	0.88	0.46–1.69	0.700	1.29	0.60–2.77	0.511	0.33	0.07–1.54	0.157
Aminoglycosides	0.72	0.35–1.47	0.362	0.84	0.38–1.84	0.656	0.15	0.01–1.84	0.139
Carbapenems	1.09	0.46–2.57	0.851	0.74	0.24–2.27	0.600	3.49	0.66–18.57	0.143
Cephalosporins	1.08	0.56–2.09	0.817	1.46	0.67–3.21	0.341	0.63	0.14–2.72	0.533
Fluoroquinolones	1.55	0.77–3.13	0.221	1.68	0.67–4.19	0.267	1.58	0.37–6.74	0.536
Penicillins	1.96	0.90–4.26	0.088	3.00	1.05–8.56	0.040	0.69	0.17–2.90	0.614
Vancomycins	0.71	0.33–1.51	0.372	0.47	0.19–1.18	0.110	2.41	0.49–11.99	0.281
Any others antibiotics	1.36	0.65–2.84	0.413	1.01	0.37–2.72	0.992	2.34	0.55–9.85	0.248
Corticosteroids	1.49	0.70–3.19	0.300	1.51	0.62–3.69	0.370	0.48	0.05–4.17	0.503
Antacids	0.37	0.05–2.99	0.353	NA			0.46	0.03–7.55	0.583
PPI	2.06	0.93–4.57	0.074	3.20	1.05–9.80	0.041	1.15	0.27–4.83	0.853
H2 receptor blockers	1.26	0.57–2.80	0.568	1.55	0.61–3.95	0.360	1.15	0.20–6.81	0.874
Diabetes	0.71	0.38–1.31	0.274	0.99	0.48–2.05	0.983	0.21	0.04–1.09	0.063
Dementia	2.52	1.16–5.50	0.020	3.42	1.38–8.49	0.008	1.52	0.18–12.47	0.699
Peptic ulcer disease	1.40	0.52–3.81	0.508	1.26	0.38–4.14	0.701	1.76	0.16–18.89	0.642
Connective tissue disease	2.87	0.71–11.64	0.140	5.10	1.19–21.81	0.028	NA
Chronic pulmonary disease	0.29	0.07–1.11	0.070	0.24	0.05–1.18	0.079	0.33	0.01–7.14	0.477
Renal disease	1.23	0.63–2.42	0.544	1.10	0.49–2.44	0.821	1.62	0.31–8.34	0.567
Liver disease	1.17	0.53–2.59	0.705	1.02	0.41–2.52	0.971	2.76	0.22–34.72	0.433
Immunocompromised status	0.56	0.23–1.37	0.200	0.62	0.22–1.71	0.353	0.10	0.00–2.92	0.180
Prior carriage of:
MRSA	0.46	0.19–1.07	0.072	0.6	0.22–1.62	0.310	0.25	0.03–2.14	0.204
VRE	1.78	0.36–8.78	0.479	NA			16.42	1.52–177.48	0.021
CRE	95.86	31.99–287.21	<0.001	109.02	28.47–417.44	<0.001	758.30	33.86–16,982.52	<0.001
MDRO	0.74	0.37–1.47	0.387	0.56	0.24–1.29	0.174	1.25	0.31–5.13	0.753

^aRef, reference; NA, not applicable. Significant P values of <0.05 are in bold.

^bFor clinical procedures and explanation of immunocompromised status, see Table 1.